• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Annual Meeting of the American Association of Swine Veterinarians >Effectiveness of a PRRS modified live virus vaccine prepared in a novel porcine alveolar macrophage cell line
【24h】

Effectiveness of a PRRS modified live virus vaccine prepared in a novel porcine alveolar macrophage cell line

机译：在新型猪肺泡巨噬细胞系中制备的PRRS改性活病毒疫苗的有效性

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The significance given by the Pork Checkoff to a new generation of PRRS virus vaccines is clearly exemplified by the prominent rank of this topic in the list of research priorities of this NPB PRRS Initiative Research Objectives. In mid-1994, the first PRRS MLV vaccine (Ingelvac PRRS MLV) was released. Since then, the use of attenuated viruses as vaccines has become customary in North America and Europe. It is well accepted that these agents are effective in conferring appropriate levels of homologous protective immunity while affording variable degrees of protection against challenge by het-erologous strains (Mengeling et al., 1996; Mengeling et al., 1999). Unfortunately, as result of patent litigation most manufacturers have ceased production of their PRRS vaccines — an action that has virtually brought to a halt the incorporation of innovations in the area of PRRS virus biologies (Hill et al., 2004). However, due to advances in the study of this pathogen, a resurgence of interest by major companies in the development of an effective PRRS vaccine can be perceived. Recently, a porcine alveolar macrophage cell line designated ZMAC-1 was developed and was found to not only be susceptible to infection by PRRS virus but also to release significant amounts of virus progeny. The aim of this study was to compare the efficacy of stocks of the MLV vaccine Prime Pac PRRS (Schering-Plough Animal Health) prepared in either ZMAC-1 or the simian cell line MARC-145, a standard immunization-challenge study was conducted.
机译：在本NPB PRRS倡议研究目标的研究优先事项列表中，本课题的突出级别明确地列出了新一代PRRS病毒疫苗的猪肉核状物疫苗的重要性。 1994年中期，第一个PRRS MLV疫苗（INGELVAC PRRS MLV）被释放。从那时起，在北美和欧洲的疫苗中使用减毒病毒已经习惯了。众所周知，这些药剂有效赋予适当水平的同源保护性免疫，同时通过HET-博发菌株的攻击来提供可变程度的保护（Mengeling等，1996; Mengeling等，1999）。遗憾的是，由于专利诉讼结果，大多数制造商都停止了他们的PRRS疫苗的生产 - 这一行动实际上已经停止了PRRS病毒生物学领域的创新（Hill等，2004）。然而，由于对该病原体研究的进展，可以察觉在开发有效的PRRS疫苗方面的主要公司感兴趣的重新提高。最近，发育了一种猪肺泡巨噬细胞系指定的ZMAC-1，并发现不仅可以易受PRRS病毒感染，而且还释放出大量的病毒后代。本研究的目的是比较MLV疫苗PRRS（Schering-Plow Animal Healt）在ZMAC-1或Simian Cell系Marc-145中制备的菌株的疗效，进行了标准免疫攻击研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号